# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, wi...
Here's a roundup of top developments in the biotech space over the last 24 hours:
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Membe...
Fluidigm Corporation (NASDAQ:FLDM) today urged Fluidigm stockholders to vote “FOR” ALL proposals related to the previously anno...
Fluidigm (NASDAQ:FLDM) reported $38.30 million in sales this quarter. This is a 14.14 percent decrease over sales of $44.61 mil...
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehens...
Fluidigm Corporation (NASDAQ:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy...
https://www.fda.gov/media/156093/download